Business Wire

31. Charles River And The Francis Crick Institute Combine Expertise In Antibody-Drug Conjugate Development 10/22/2025

    Charles River Laboratories International, Inc. and The Francis Crick Institute (Crick) today announced a new collaboration around Antibody-Drug Conjugate (ADC) drug discovery and development, leveraging combined strengths to accelerate the development and delivery of next-generation targeted therapies.

32. Ventus Therapeutics Enters Into A Collaboration And License Agreement With Genentech To Discover And Develop Small-Molecule Medicines Using Ventus' ReSOLVE Platform 10/21/2025

    Ventus Therapeutics, a clinical-stage biopharmaceutical company advancing two Phase 2 small-molecule programs for immunological, inflammatory, and neurological disorders, today announced a multi-year collaboration with Genentech, a member of the Roche Group, to discover and optimize novel small-molecule candidates for challenging targets in major disease areas using Ventus’ proprietary drug discovery platform, ReSOLVE.

33. Samsung Bioepis And Phrontline Announce A Global Strategic Partnership To Advance Best-In-Class Antibody-Drug Conjugate Therapeutics For Solid Tumors 10/20/2025

    Samsung Bioepis Co., Ltd. and Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the companies have entered into a global collaboration agreement to develop, manufacture and commercialize two ADC assets: TJ108, bispecific and dual-payload ADC, and another asset to be named.

34. Charles River And X-Chem Announce Strategic Collaboration To Enhance Hit Identification Capabilities 10/20/2025

    Charles River Laboratories International, Inc. today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and accelerate the discovery of novel therapeutics.

35. Indivi And Clouds Of Care Partner To Advance Deep Phenotyping In Early Alzheimer's And Parkinson's Drug Development 10/15/2025

    Indivi and Clouds of Care, two independent TechBio companies, today announced a strategic partnership to advance the use of precision medicine tools in early-phase neuroscience drug development, targeting Alzheimer’s and Parkinson’s disease.

36. Syncell Expands European Market Presence To Advance Disease Research And Drug Discovery 10/14/2025

    Syncell Inc., a leader in next-generation unbiased subcellular proteomics analysis, today announced the deployment of its commercial Microscoop Mint technology at two of Europe’s foremost research institutes in proteomics and advanced technology adoption.

37. insitro Extends Research Collaboration With Bristol Myers Squibb Leveraging insitro's ChemML Discovery Platform 10/14/2025

    insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb, today announced the next phase of their collaboration to discover new molecules with potential as new treatments for amyotrophic lateral sclerosis (ALS).

38. BenchSci Announces Three-Year License Agreement With Sanofi To Access And Use BenchSci's ASCEND Platform 10/8/2025

    BenchSci, a world leader in AI solutions for preclinical research and drug discovery, today announced a three-year agreement with Sanofi to deploy and use BenchSci’s ASCEND platform across Sanofi’s global preclinical research organization.

39. Algen Biotechnologies Announces Multi-Target Partnership To Advance AI-Powered Drug Discovery In Immunology With AstraZeneca 10/6/2025

    Algen Biotechnologies, a biotechnology company pioneering next-generation therapies using advanced CRISPR gene modulation and AI-driven drug discovery, today announced a multi-target partnership with AstraZeneca to accelerate the discovery of novel therapeutic targets in immunology.

40. QuantHealth Secures Strategic Investment From Sanofi Ventures To Accelerate AI-Driven Clinical Trials 10/1/2025

    QuantHealth, a pioneer in AI-driven clinical trial simulation, announced a strategic investment from Sanofi Ventures, the venture capital arm of global healthcare leader Sanofi. The investment will accelerate QuantHealth’s efforts to bring scalable, patient-level simulations and digital twin technologies to the forefront of drug development, bringing its total funds raised to $30M.